BrainStorm Cell Therapeutics Inc. is a biotechnology company pioneering the development of autologous cell therapies for neurodegenerative diseases. The company's lead product, NurOwn®, is a personalized cell therapy derived from the patient's own bone marrow stromal cells (MSCs) that are engineered to secrete high levels of neurotrophic factors. BrainStorm's approach represents a novel therapeutic strategy that combines cell therapy with gene therapy concepts, using the patient's own cells as a manufacturing platform for delivering regenerative factors directly to the central nervous system[1].
The company focuses on diseases where neurotrophic factor deficiency plays a key role in disease progression, particularly amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease. BrainStorm's technology platform addresses a critical unmet need in neurodegenerative disease — the progressive loss of neuronal function due to reduced trophic support.
BrainStorm's proprietary technology platform, MSC-NTF (Mesenchymal Stromal Cells engineered to secrete NeuroTrophic Factors), represents a significant advancement in cell-based therapeutics:
The therapeutic benefit of NurOwn derives from multiple mechanisms:
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| NurOwn (MSC-NTF) | Autologous MSC-NTF cells | ALS | Phase 3 | Completed |
| NurOwn | Autologous MSC-NTF cells | Progressive MS | Phase 1 | Active |
| NurOwn | Autologous MSC-NTF cells | Alzheimer's Disease | Preclinical | Planning |
NurOwn has undergone extensive clinical evaluation in ALS:
Phase 2 Trial (2018): An open-label, single-arm study demonstrated safety and suggested efficacy. Patients showed slower progression on the ALSFRS-R scale compared to historical controls, with responders identified as those maintaining or improving function[2].
Phase 3 Trial (2020-2022): The pivotal Phase 3 trial enrolled approximately 200 patients with ALS at multiple U.S. sites. While the trial did not meet its primary endpoint of a statistically significant difference in response rate at 28 weeks, pre-specified subgroup analyses revealed clinically meaningful benefits in patients with less advanced disease (baseline ALSFRS-R ≥ 35). These patients showed significantly better outcomes in function, breathing, and quality of measures[3].
BrainStorm is conducting an open-label Phase 1 trial evaluating NurOwn in patients with progressive forms of MS. The trial aims to assess safety and explore potential neuroprotective effects in a disease characterized by demyelination and neuronal loss.
Preclinical studies have explored NurOwn in Alzheimer's disease models, demonstrating reduced neuroinflammation and improved cognitive function. The company has announced plans to advance this program based on these findings.
BrainStorm has pursued a strategic funding approach to support its clinical programs:
BrainStorm's cell therapy approach occupies a unique position in the ALS treatment landscape:
The autologous nature of NurOwn provides potential advantages in safety and immune tolerance compared to allogeneic or synthetic therapies.
BrainStorm faces several challenges and opportunities: